AGM Statement

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices Company's headquarters, Unit 1b Lynx Business Park, Fordham Road Snailwell, Newmarket, Cambridgeshire, CB8 7NY.

Matt Sassone, Chief Executive Officer, will address the meeting with the following update:

"I am pleased to report that the Company has made a strong start to the new financial year. Trading is in line with expectations and in the first five months we remain firmly on target to deliver revenue growth of at least 10% year-on-year. As in prior years, we expect a greater weighting of revenue and profit contribution in the second half driven by winter seasonal demand across our hospital customer base.

"We are seeing strong volume momentum, underpinned by solid growth in the UK and accelerating demand across Europe, as customers increasingly adopt our chlorine dioxide technologies and our enhanced commercial execution delivers results. It is pleasing to see increasing demand across Europe, given it is the cornerstone of our international business.

"In the United States, we are seeing clear evidence of traction and scale-up potential. Sales of Tristel ULT™ in the first five months of this year are already equivalent to the full-year contribution achieved last year, and Tristel OPH™ has made an excellent start following its launch into the ophthalmology market. Together, these developments have resulted in a 510% increase in total US revenue versus the prior year-to-date. The recognition of our technology in national guidelines for the American Institute of Ultrasound in Medicine, combined with our expanded portfolio offering in the US market, gives us confidence in our ability to build a meaningful and sizeable business in the world's largest healthcare market.

"We remain ambitious, confident and focused on delivery, and look forward to updating shareholders further at our Interim Results in early March."